
Nanobiotix SA (NBTX) Stock Forecast & Price Target
Nanobiotix SA (NBTX) Analyst Ratings
Bulls say
Nanobiotix is a company with promising potential, as its physics-based approach to developing nanotherapeutics has the potential to revolutionize cancer treatment. However, the company faces risks, including potential clinical trial failures and regulatory setbacks, as well as potential financial risks due to its high debt and potential need for dilutive financing. The company also faces competition in the market and uncertainties around commercial performance of its products. However, with near-term milestones and potential collaborations, Nanobiotix is positioned for growth and success in the future.
Bears say
Nanobiotix is facing potential risks and a negative outlook due to potential clinical trial failures, safety concerns, and regulatory setbacks for its pipeline candidates. Additionally, commercial performance for its lead program may not meet expectations as it is highly novel, which could result in lower revenues and profitability. Furthermore, the company carries a high level of financial risk as it relies heavily on milestone payments and royalties rather than consistent, solid revenues from approved products.
This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.
Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction
Start investing in Nanobiotix SA (NBTX)
Order type
Buy in
Order amount
Est. shares
0 shares